Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

194 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Prognostic Value of Body Mass Index in Stage II/III Colon Cancer: Posthoc Analysis From the TOSCA Trial.
Basile D, Rosati G, Bergamo F, Garattini SK, Banzi M, Zampino M, Bozzarelli S, Marchetti P, Galli F, Galli F, Longarini R, Zaniboni A, Ferrari D, De Placido S, Frassineti LG, Nicolini M, Cinieri S, Priscindiaro M, Ziranu P, Caccialanza R, Pastorino A, Mosconi S, Aprile G. Basile D, et al. Among authors: pastorino a. Clin Colorectal Cancer. 2023 Jun;22(2):190-198. doi: 10.1016/j.clcc.2023.01.004. Epub 2023 Feb 5. Clin Colorectal Cancer. 2023. PMID: 36935327 Clinical Trial.
Proxies of quality of life in metastatic colorectal cancer: analyses in the RECOURSE trial.
Van Cutsem E, Falcone A, Garcia-Carbonero R, Komatsu Y, Pastorino A, Peeters M, Shimada Y, Yamazaki K, Yoshino T, Zaniboni A, Amellal N, Kanehisa A, Winkler R, Makris L, Mayer RJ, Ohtsu A, Tabernero J. Van Cutsem E, et al. Among authors: pastorino a. ESMO Open. 2017 Nov 23;2(5):e000261. doi: 10.1136/esmoopen-2017-000261. eCollection 2017. ESMO Open. 2017. PMID: 29215098 Free PMC article.
Aflibercept Plus FOLFIRI in the Real-life Setting: Safety and Quality of Life Data From the Italian Patient Cohort of the Aflibercept Safety and Quality-of-Life Program Study.
Pastorino A, Di Bartolomeo M, Maiello E, Iaffaioli V, Ciuffreda L, Fasola G, Di Costanzo F, Frassineti GL, Marchetti P, Antoniotti C, Leone F, Zaniboni A, Aprile G, Zilocchi C, Sobrero A, Bordonaro R. Pastorino A, et al. Clin Colorectal Cancer. 2018 Sep;17(3):e457-e470. doi: 10.1016/j.clcc.2018.03.002. Epub 2018 Mar 8. Clin Colorectal Cancer. 2018. PMID: 29605592 Free article. Clinical Trial.
Oxaliplatin plus fluoropyrimidines as adjuvant therapy for colon cancer in older patients: A subgroup analysis from the TOSCA trial.
Rosati G, Lonardi S, Galli F, Di Bartolomeo M, Ronzoni M, Zampino MG, Banzi M, Zaniboni A, Pasini F, Bozzarelli S, Garattini SK, Ferrari D, Montesarchio V, Mambrini A, Ciuffreda L, Galli F, Pusceddu V, Carlomagno C, Bidoli P, Amoroso D, Bochicchio AM, Frassineti L, Corsi D, Bilancia D, Pastorino A, De Stefano A, Labianca R; TOSCA (Three or Six Colon Adjuvant) investigators. Rosati G, et al. Among authors: pastorino a. Eur J Cancer. 2021 May;148:190-201. doi: 10.1016/j.ejca.2021.01.051. Epub 2021 Mar 18. Eur J Cancer. 2021. PMID: 33744715
Durvalumab Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in Biliary Tract Cancer: a Real-World Retrospective, Multicenter Study.
Rimini M, Masi G, Lonardi S, Nichetti F, Pressiani T, Lavacchi D, Jessica L, Giordano G, Scartozzi M, Tamburini E, Pastorino A, Rapposelli IG, Daniele B, Martinelli E, Garajova I, Aprile G, Schirripa M, Formica V, Salani F, Winchler C, Bergamo F, Balsano R, Gusmaroli E, Lorenzo A, Landriscina M, Pretta A, Toma I, Pirrone C, Diana A, Leone F, Brunetti O, Brandi G, Garattini SK, Satolli MA, Rossari F, Fornaro L, Niger M, Zanuso V, De Rosa A, Ratti F, Aldrighetti L, De Braud F, Foti S, Rizzato MD, Vivaldi C, Stefano C, Rimassa L, Antonuzzo L, Casadei-Gardini A. Rimini M, et al. Among authors: pastorino a. Target Oncol. 2024 May 1. doi: 10.1007/s11523-024-01060-1. Online ahead of print. Target Oncol. 2024. PMID: 38691295
Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: An early exploratory analysis of real-world data.
Rimini M, Fornaro L, Lonardi S, Niger M, Lavacchi D, Pressiani T, Lucchetti J, Giordano G, Pretta A, Tamburini E, Pirrone C, Rapposelli IG, Diana A, Martinelli E, Garajová I, Simionato F, Schirripa M, Formica V, Vivaldi C, Caliman E, Rizzato MD, Zanuso V, Nichetti F, Angotti L, Landriscina M, Scartozzi M, Ramundo M, Pastorino A, Daniele B, Cornara N, Persano M, Gusmaroli E, Cerantola R, Salani F, Ratti F, Aldrighetti L, Cascinu S, Rimassa L, Antonuzzo L, Casadei-Gardini A. Rimini M, et al. Among authors: pastorino a. Liver Int. 2023 Aug;43(8):1803-1812. doi: 10.1111/liv.15641. Liver Int. 2023. PMID: 37452505
Radiological imaging markers predicting clinical outcome in patients with metastatic colorectal carcinoma treated with regorafenib: post hoc analysis of the CORRECT phase III trial (RadioCORRECT study).
Ricotta R, Verrioli A, Ghezzi S, Porcu L, Grothey A, Falcone A, Van Cutsem E, Argilés G, Adenis A, Ychou M, Barone C, Bouché O, Peeters M, Humblet Y, Mineur L, Sobrero AF, Hubbard JM, Cremolini C, Prenen H, Tabernero J, Jarraya H, Mazard T, Deguelte-Lardiere S, Papadimitriou K, Van den Eynde M, Pastorino A, Redaelli D, Bencardino K, Funaioli C, Amatu A, Carlo-Stella G, Torri V, Sartore-Bianchi A, Vanzulli A, Siena S. Ricotta R, et al. Among authors: pastorino a. ESMO Open. 2017 Feb 13;1(6):e000111. doi: 10.1136/esmoopen-2016-000111. eCollection 2016. ESMO Open. 2017. PMID: 28848658 Free PMC article.
The outcome to axitinib or everolimus after sunitinib in metastatic renal cell carcinoma.
Iacovelli R, Cossu Rocca M, Galli L, Sabbatini R, De Giorgi U, Santini D, Facchini G, Mosca A, Atzori F, Zucali P, Fornarini G, Massari F, Buti S, Ricotta R, Masini C, Toscani I, Biasco E, Guida A, Lolli C, De Lisi D, Rossetti S, Terrone C, Scartozzi M, Miggiano C, Pastorino A, Bersanelli M, Carlo-Stella G, Pinto C, Nobili E, Nolè F, Tortora G, Porta C. Iacovelli R, et al. Among authors: pastorino a. Anticancer Drugs. 2018 Aug;29(7):705-709. doi: 10.1097/CAD.0000000000000632. Anticancer Drugs. 2018. PMID: 29846246
Non-Operative Management Versus Total Mesorectal Excision for Locally Advanced Rectal Cancer with Clinical Complete Response After Neoadjuvant Chemoradiotherapy: a GRADE Approach by the Rectal Cancer Guidelines Writing Group of the Italian Association of Medical Oncology (AIOM).
Capelli G, De Simone I, Spolverato G, Cinquini M, Moschetti I, Lonardi S, Masi G, Carlomagno C, Corsi D, Luppi G, Gambacorta MA, Valvo F, Cannizzaro R, Grillo F, Barbaro B, Restivo A, Messina M, Pastorino A, Aschele C, Pucciarelli S. Capelli G, et al. Among authors: pastorino a. J Gastrointest Surg. 2020 Sep;24(9):2150-2159. doi: 10.1007/s11605-020-04635-1. Epub 2020 May 11. J Gastrointest Surg. 2020. PMID: 32394125 Free article. Review.
194 results